The struggle within: Microbial influences on colorectal cancer

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 396-409

  Arthur, Janelle C ^a   Jobin, Christian ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

colorectal cancer; inflammatory bowel disease; intestinal microbiota

Indexed keywords

BACTERIAL TOXIN;

BACTERIUM; CARCINOGENESIS; COLITIS; COLORECTAL CANCER; COMMUNITY STRUCTURE; DISEASE ASSOCIATION; HOST; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; METAGENOMICS; MICROBIAL COMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSOR; SYMBIONT;

BACTERIA; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; METAGENOME;

EID: 78650118403     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21354     Document Type: Review

References (239)

1. Rakoff-Nahoum S, Hao L, Medzhitov R,. Role of Toll-like receptors in spontaneous commensal-dependent colitis. Immunity. 2006; 25: 319-329.
2. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998; 66: 5224-5231.
3. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994; 180: 2359-2364.
4. Dianda L, Hanby AM, Wright NA, et al. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol. 1997; 150: 91-97.
5. Mathew CG,. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet. 2008; 9: 9-14.
6. Cho JH,. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008; 8: 458-466.
7. Neish AS,. Microbes in gastrointestinal health and disease. Gastroenterology. 2009; 136: 65-80.
8. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001; 291: 881-884.
9. Hooper LV, Gordon JI,. Commensal host-bacterial relationships in the gut. Science. 2001; 292: 1115-1118.
10. Hamady M, Knight R,. Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res. 2009; 19: 1141-1152.
11. Hamady M, Walker JJ, Harris JK, et al. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods. 2008; 5: 235-237.
12. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005; 308: 1635-1638.
13. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009; 457: 480-484.
14. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005; 102: 11070-11075.
15. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006; 312: 1355-1359.
16. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007; 104: 13780-13785.
17. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007; 449: 804-810.
18. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464: 59-65.
19. Crawford PA, Crowley JR, Sambandam N, et al. Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. Proc Natl Acad Sci U S A. 2009; 106: 11276-11281.
20. Stappenbeck TS, Hooper LV, Gordon JI,. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A. 2002; 99: 15451-15455.
21. Clarke TB, Davis KM, Lysenko ES, et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med. 2010; 16: 228-231.
22. Strober W,. The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity. 2009; 31: 377-388.
23. Chervonsky AV,. Influence of microbial environment on autoimmunity. Nat Immunol. 2010; 11: 28-35.
24. Eberl G, Lochner M,. The development of intestinal lymphoid tissues at the interface of self and microbiota. Mucosal Immunol. 2009; 2: 478-485.
25. Cani PD, Delzenne NM,. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol. 2009; 9: 737-743.
26. Hooper LV, Midtvedt T, Gordon JI,. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002; 22: 283-307.
27. Hooper LV,. Bacterial contributions to mammalian gut development. Trends Microbiol. 2004; 12: 129-134.
28. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444: 1022-1023.
29. Turnbaugh PJ, Backhed F, Fulton L, et al. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008; 3: 213-223.
30. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444: 1027-1031.
31. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006; 103: 12511-12516.
32. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008; 455: 1109-1113.
33. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010; 5: e9085.
34. Sidhu H, Allison MJ, Chow JM, et al. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol. 2001; 166: 1487-1491.
35. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest. 2008; 118: 205-216.
36. Tannock GW,. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol. 2008; 1 (suppl 1): S15-18.
37. Uronis JM, Jobin C,. Microbes and colorectal cancer: is there a relationship? Curr Oncol. 2009; 16: 22-24.
38. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004; 53: 685-693.
39. Ott SJ, Plamondon S, Hart A, et al. Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol. 2008; 46: 3510-3513.
40. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006; 55: 205-211.
41. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007; 131: 33-45.
42. Garrett WS, Punit S, Gallini CA, et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell. 2009; 16: 208-219.
43. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010; 328: 228-231.
44. Moser AR, Pitot HC, Dove WF,. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990; 247: 322-324.
45. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992; 256: 668-670.
46. Dove WF, Clipson L, Gould KA, et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 1997; 57: 812-814.
47. Uronis JM, Muhlbauer M, Herfarth HH, et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One. 2009; 4: e6026.
48. Rao VP, Poutahidis T, Ge Z, et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 2006; 66: 7395-7400.
49. Erdman SE, Poutahidis T, Tomczak M, et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol. 2003; 162: 691-702.
50. Erdman SE, Rao VP, Poutahidis T, et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 2003; 63: 6042-6050.
51. -/- mice results in colitis that progresses to dysplasia. Am J Pathol. 2005; 166: 1793-1806.
52. -/-) mice. Am J Pathol. 2002; 160: 739-751.
53. Chichlowski M, Sharp JM, Vanderford DA, et al. Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. Comp Med. 2008; 58: 534-541.
54. Waisberg J, Matheus Cde O, Pimenta J,. Infectious endocarditis from Streptococcus bovis associated with colonic carcinoma: case report and literature review. Arq Gastroenterol. 2002; 39: 177-180.
55. Gold JS, Bayar S, Salem RR,. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. Arch Surg. 2004; 139: 760-765.
56. Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med. 1977; 297: 800-802.
57. Zarkin BA, Lillemoe KD, Cameron JL, et al. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg. 1990; 211: 786-791; discussion 791-782.
58. Ruoff KL, Miller SI, Garner CV, et al. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol. 1989; 27: 305-308.
59. Ellmerich S, Scholler M, Duranton B, et al. Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis. 2000; 21: 753-756.
60. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009; 15: 1016-1022.
61. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology. 2004; 127: 80-93.
62. Luperchio SA, Schauer DB,. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect. 2001; 3: 333-340.
63. Barthold SW, Jonas AM,. Morphogenesis of early 1, 2-dimethylhydrazine- induced lesions and latent period reduction of colon carcinogenesis in mice by a variant of Citrobacter freundii. Cancer Res. 1977; 37: 4352-4360.
64. Min/+ mice. J Infect Dis. 2001; 184: 227-230.
65. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342: 575-577.
66. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338: 1175-1176.
67. Weber DM, Dimopoulos MA, Anandu DP, et al. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology. 1994; 107: 1835-1838.
68. Montalban C, Santon A, Boixeda D, et al. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut. 2001; 49: 584-587.
69. Erdman SE, Correa P, Coleman LA, et al. Helicobacter mustelae-associated gastric MALT lymphoma in ferrets. Am J Pathol. 1997; 151: 273-280.
70. Marshall BJ, Warren JR,. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1: 1311-1315.
71. Watanabe T, Tada M, Nagai H, et al. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology. 1998; 115: 642-648.
72. Kobayashi M, Lee H, Schaffer L, et al. A distinctive set of genes is upregulated during the inflammation-carcinoma sequence in mouse stomach infected by Helicobacter felis. J Histochem Cytochem. 2007; 55: 263-274.
73. Hooper SJ, Crean SJ, Lewis MA, et al. Viable bacteria present within oral squamous cell carcinoma tissue. J Clin Microbiol. 2006; 44: 1719-1725.
74. Narikiyo M, Tanabe C, Yamada Y, et al. Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers. Cancer Sci. 2004; 95: 569-574.
75. Morita E, Narikiyo M, Yano A, et al. Different frequencies of Streptococcus anginosus infection in oral cancer and esophageal cancer. Cancer Sci. 2003; 94: 492-496.
76. Sasaki H, Ishizuka T, Muto M, et al. Presence of Streptococcus anginosus DNA in esophageal cancer, dysplasia of esophagus, and gastric cancer. Cancer Res. 1998; 58: 2991-2995.
77. Sasaki M, Yamaura C, Ohara-Nemoto Y, et al. Streptococcus anginosus infection in oral cancer and its infection route. Oral Dis. 2005; 11: 151-156.
78. Ward JM, Fox JG, Anver MR, et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst. 1994; 86: 1222-1227.
79. Theve EJ, Feng Y, Taghizadeh K, et al. Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus. Infect Immun. 2008; 76: 4071-4078.
80. Sipowicz MA, Weghorst CM, Shiao YH, et al. Lack of p53 and ras mutations in Helicobacter hepaticus-induced liver tumors in A/JCr mice. Carcinogenesis. 1997; 18: 233-236.
81. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001; 51: 349-364.
82. Welton JC, Marr JS, Friedman SM,. Association between hepatobiliary cancer and typhoid carrier state. Lancet. 1979; 1: 791-794.
83. Caygill CP, Hill MJ, Braddick M, et al. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet. 1994; 343: 83-84.
84. Dutta U, Garg PK, Kumar R, et al. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol. 2000; 95: 784-787.
85. Shukla VK, Singh H, Pandey M, et al. Carcinoma of the gallbladder-is it a sequel of typhoid? Dig Dis Sci. 2000; 45: 900-903.
86. Littman AJ, White E, Jackson LA, et al. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1624-1630.
87. Koyi H, Branden E, Gnarpe J, et al. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. APMIS. 2001; 109: 572-580.
88. Kocazeybek B,. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. J Med Microbiol. 2003; 52: 721-726.
89. Verbeke P, Welter-Stahl L, Ying S, et al. Recruitment of BAD by the Chlamydia trachomatis vacuole correlates with host-cell survival. PLoS Pathog. 2006; 2: e45.
90. Fischer SF, Harlander T, Vier J, et al. Protection against CD95-induced apoptosis by chlamydial infection at a mitochondrial step. Infect Immun. 2004; 72: 1107-1115.
91. Rajalingam K, Al-Younes H, Muller A, et al. Epithelial cells infected with Chlamydophila pneumoniae (Chlamydia pneumoniae) are resistant to apoptosis. Infect Immun. 2001; 69: 7880-7888.
92. Smith DG, Lawson GH,. Lawsonia intracellularis: getting inside the pathogenesis of proliferative enteropathy. Vet Microbiol. 2001; 82: 331-345.
93. Tsai S, Wear DJ, Shih JW, et al. Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Proc Natl Acad Sci U S A. 1995; 92: 10197-10201.
94. Feng SH, Tsai S, Rodriguez J, et al. Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol. 1999; 19: 7995-8002.
95. Gerlic M, Horowitz J, Horowitz S,. Mycoplasma fermentans inhibits tumor necrosis factor alpha-induced apoptosis in the human myelomonocytic U937 cell line. Cell Death Differ. 2004; 11: 1204-1212.
96. Zhang B, Shih JW, Wear DJ, et al. High-level expression of H-ras and c-myc oncogenes in mycoplasma-mediated malignant cell transformation. Proc Soc Exp Biol Med. 1997; 214: 359-366.
97. Dehio C, Sander A,. Bartonella as emerging pathogens. Trends Microbiol. 1999; 7: 226-228.
98. Geijtenbeek TB, van Vliet SJ, Engering A, et al. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol. 2004; 22: 33-54.
99. Abreu MT, Fukata M, Arditi M,. TLR signaling in the gut in health and disease. J Immunol. 2005; 174: 4453-4460.
100. Ishii KJ, Akira S,. Potential link between the immune system and metabolism of nucleic acids. Curr Opin Immunol. 2008; 20: 524-529.
101. Rakoff-Nahoum S, Medzhitov R,. Innate immune recognition of the indigenous microbial flora. Mucosal Immunol. 2008; 1 (suppl 1): S10-14.
102. Carpenter S, O'Neill LA,. How important are Toll-like receptors for antimicrobial responses? Cell Microbiol. 2007; 9: 1891-1901.
103. Le Bourhis L, Benko S, Girardin SE,. Nod1 and Nod2 in innate immunity and human inflammatory disorders. Biochem Soc Trans. 2007; 35: 1479-1484.
104. Kopp E, Medzhitov R,. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol. 2003; 15: 396-401.
105. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998; 2: 253-258.
106. EGFP mice reveal the critical role of TLR/NF-kappa B signaling in commensal bacteria-induced colitis. J Immunol. 2007; 178: 6522-6532.
107. Rakoff-Nahoum S, Medzhitov R,. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007; 317: 124-127.
108. Brown SL, Riehl TE, Walker MR, et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest. 2007; 117: 258-269.
109. Pull SL, Doherty JM, Mills JC, et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A. 2005; 102: 99-104.
110. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007; 133: 1869-1881.
111. Fukata M, Hernandez Y, Conduah D, et al. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis. 2009; 15: 997-1006.
112. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet. 2009; 41: 71-76.
113. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603.
114. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603-606.
115. McGovern DP, Hysi P, Ahmad T, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 2005; 14: 1245-1250.
116. De Jager PL, Franchimont D, Waliszewska A, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun. 2007; 8: 387-397.
117. Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008; 118: 545-559.
118. Yang Z, Fuss IJ, Watanabe T, et al. NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology. 2007; 133: 1510-1521.
119. Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A. 2009; 106: 15813-15818.
120. Tian Y, Li Y, Hu Z, et al. Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis. Int J Colorectal Dis. 2010; 25: 161-168.
121. Mockelmann N, von Schonfels W, Buch S, et al. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC Gastroenterol. 2009; 9: 79.
122. Chen GY, Shaw MH, Redondo G, et al. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 2008; 68: 10060-10067.
123. Allen IC, McElvania Tekippe E, Woodford R-MT, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis associated cancer. J Exp Med. 2010.
124. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15: 103-113.
125. Uronis JM, Muehlbauer M, Keku TO, et al. Intestinal inflammation is not sufficient to promote the development of colitis associated colorectal cancer: role of the enteric microbiota. Digestive Diseases Week, New Orleans, LA; 2010.
126. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004; 53: 1813-1816.
127. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535.
128. Toprak NU, Yagci A, Gulluoglu BM, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect. 2006; 12: 782-786.
129. Ge Z, Rogers AB, Feng Y, et al. Bacterial cytolethal distending toxin promotes the development of dysplasia in a model of microbially induced hepatocarcinogenesis. Cell Microbiol. 2007; 9: 2070-2080.
130. Haghjoo E, Galan JE,. Salmonella typhi encodes a functional cytolethal distending toxin that is delivered into host cells by a bacterial- internalization pathway. Proc Natl Acad Sci U S A. 2004; 101: 4614-4619.
131. Bielaszewska M, Sinha B, Kuczius T, et al. Cytolethal distending toxin from Shiga toxin-producing Escherichia coli O157 causes irreversible G2/M arrest, inhibition of proliferation, and death of human endothelial cells. Infect Immun. 2005; 73: 552-562.
132. Comayras C, Tasca C, Peres SY, et al. Escherichia coli cytolethal distending toxin blocks the HeLa cell cycle at the G2/M transition by preventing cdc2 protein kinase dephosphorylation and activation. Infect Immun. 1997; 65: 5088-5095.
133. Sert V, Cans C, Tasca C, et al. The bacterial cytolethal distending toxin (CDT) triggers a G2 cell cycle checkpoint in mammalian cells without preliminary induction of DNA strand breaks. Oncogene. 1999; 18: 6296-6304.
134. Marches O, Ledger TN, Boury M, et al. Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. Mol Microbiol. 2003; 50: 1553-1567.
135. Samba-Louaka A, Nougayrede JP, Watrin C, et al. The enteropathogenic Escherichia coli effector Cif induces delayed apoptosis in epithelial cells. Infect Immun. 2009; 77: 5471-5477.
136. Jubelin G, Chavez CV, Taieb F, et al. Cycle inhibiting factors (CIFs) are a growing family of functional cyclomodulins present in invertebrate and mammal bacterial pathogens. PLoS One. 2009; 4: e4855.
137. Nougayrede JP, Boury M, Tasca C, et al. Type III secretion-dependent cell cycle block caused in HeLa cells by enteropathogenic Escherichia coli O103. Infect Immun. 2001; 69: 6785-6795.
138. Fiorentini C, Matarrese P, Straface E, et al. Toxin-induced activation of Rho GTP-binding protein increases Bcl-2 expression and influences mitochondrial homeostasis. Exp Cell Res. 1998; 242: 341-350.
139. Miraglia AG, Travaglione S, Meschini S, et al. Cytotoxic necrotizing factor 1 prevents apoptosis via the Akt/IkappaB kinase pathway: role of nuclear factor-kappaB and Bcl-2. Mol Biol Cell. 2007; 18: 2735-2744.
140. Doye A, Mettouchi A, Bossis G, et al. CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion. Cell. 2002; 111: 553-564.
141. Higgins TE, Murphy AC, Staddon JM, et al. Pasteurella multocida toxin is a potent inducer of anchorage-independent cell growth. Proc Natl Acad Sci U S A. 1992; 89: 4240-4244.
142. Lax AJ, Grigoriadis AE,. Pasteurella multocida toxin: the mitogenic toxin that stimulates signalling cascades to regulate growth and differentiation. Int J Med Microbiol. 2001; 291: 261-268.
143. Sugai M, Chen CH, Wu HC,. Bacterial ADP-ribosyltransferase with a substrate specificity of the rho protein disassembles the Golgi apparatus in Vero cells and mimics the action of brefeldin A. Proc Natl Acad Sci U S A. 1992; 89: 8903-8907.
144. Sugai M, Hashimoto K, Kikuchi A, et al. Epidermal cell differentiation inhibitor ADP-ribosylates small GTP-binding proteins and induces hyperplasia of epidermis. J Biol Chem. 1992; 267: 2600-2604.
145. Bagnoli F, Buti L, Tompkins L, et al. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci U S A. 2005; 102: 16339-16344.
146. Segal ED, Cha J, Lo J, et al. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci U S A. 1999; 96: 14559-14564.
147. Peek RM Jr, Vaezi MF, Falk GW, et al. Role of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. Int J Cancer. 1999; 82: 520-524.
148. Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003; 125: 1636-1644.
149. Takada H, Hirooka T, Hiramatsu Y, et al. Effect of beta-glucuronidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats. Cancer Res. 1982; 42: 331-334.
150. Humblot C, Murkovic M, Rigottier-Gois L, et al. Beta-glucuronidase in human intestinal microbiota is necessary for the colonic genotoxicity of the food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline in rats. Carcinogenesis. 2007; 28: 2419-2425.
151. Kim DH, Jin YH,. Intestinal bacterial beta-glucuronidase activity of patients with colon cancer. Arch Pharm Res. 2001; 24: 564-567.
152. Mirvish SS, Haorah J, Zhou L, et al. Total N-nitroso compounds and their precursors in hot dogs and in the gastrointestinal tract and feces of rats and mice: possible etiologic agents for colon cancer. J Nutr. 2002; 132: 3526S-3529S.
153. Bingham SA, Pignatelli B, Pollock JR, et al. Does increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon cancer? Carcinogenesis. 1996; 17: 515-523. (Pubitemid 26085332)
154. Archer MC,. Mechanisms of action of N-nitroso compounds. Cancer Surv. 1989; 8: 241-250.
155. Xu H, Heinze TM, Chen S, et al. Anaerobic metabolism of 1-amino-2-naphthol-based azo dyes (Sudan dyes) by human intestinal microflora. Appl Environ Microbiol. 2007; 73: 7759-7762.
156. Chung KT, Stevens SE Jr, Cerniglia CE,. The reduction of azo dyes by the intestinal microflora. Crit Rev Microbiol. 1992; 18: 175-190.
157. Caderni G, Femia AP, Giannini A, et al. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res. 2003; 63: 2388-2392.
158. Femia AP, Dolara P, Caderni G,. Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis. Carcinogenesis. 2004; 25: 277-281.
159. Femia AP, Dolara P, Giannini A, et al. Frequent mutation of Apc gene in rat colon tumors and mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis. Cancer Res. 2007; 67: 445-449.
160. de Moreno de LeBlanc A, LeBlanc JG, Perdigon G, et al. Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice. J Med Microbiol. 2008; 57: 100-105.
161. Wang X, Allen TD, May RJ, et al. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res. 2008; 68: 9909-9917.
162. McGarr SE, Ridlon JM, Hylemon PB,. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol. 2005; 39: 98-109.
163. Bayerdorffer E, Mannes GA, Ochsenkuhn T, et al. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut. 1995; 36: 268-273.
164. Bayerdorffer E, Mannes GA, Richter WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology. 1993; 104: 145-151. (Pubitemid 23040017)
165. Reddy BS, Watanabe K, Weisburger JH, et al. Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res. 1977; 37: 3238-3242. (Pubitemid 8169906)
166. Pai R, Tarnawski AS, Tran T,. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell. 2004; 15: 2156-2163.
167. Reddy BS, Wynder EL,. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer. 1977; 39: 2533-2539.
168. Flynn C, Montrose DC, Swank DL, et al. Deoxycholic acid promotes the growth of colonic aberrant crypt foci. Mol Carcinog. 2007; 46: 60-70.
169. Laqueur GL, McDaniel EG, Matsumoto H,. Tumor induction in germfree rats with methylazoxymethanol (MAM) and synthetic MAM acetate. J Natl Cancer Inst. 1967; 39: 355-371.
170. Rowland IR,. The role of the gastrointestinal microbiota in colorectal cancer. Curr Pharm Des. 2009; 15: 1524-1527.
171. Fiala ES,. Investigations into the metabolism and mode of action of the colon carcinogens 1,2-dimethylhydrazine and azoxymethane. Cancer. 1977; 40: 2436-2445.
172. Weisburger JH,. Colon carcinogens: their metabolism and mode of action. Cancer. 1971; 28: 60-70.
173. Neufert C, Becker C, Neurath MF,. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007; 2: 1998-2004.
174. Van Tassell RL, Kingston DG, Wilkins TD,. Metabolism of dietary genotoxins by the human colonic microflora; the fecapentaenes and heterocyclic amines. Mutat Res. 1990; 238: 209-221.
175. Vanhaecke L, Vercruysse F, Boon N, et al. Isolation and characterization of human intestinal bacteria capable of transforming the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Appl Environ Microbiol. 2008; 74: 1469-1477.
176. Kassie F, Rabot S, Kundi M, et al. Intestinal microflora plays a crucial role in the genotoxicity of the cooked food mutagen 2-amino-3-methylimidazo [4,5-f]quinoline. Carcinogenesis. 2001; 22: 1721-1725.
177. Knasmuller S, Steinkellner H, Hirschl AM, et al. Impact of bacteria in dairy products and of the intestinal microflora on the genotoxic and carcinogenic effects of heterocyclic aromatic amines. Mutat Res. 2001; 480-481: 129-138.
178. Ivanov, II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008; 4: 337-349.
179. Nagamine CM, Rogers AB, Fox JG, et al. Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. Int J Cancer. 2008; 122: 832-838.
180. Maggio-Price L, Treuting P, Zeng W, et al. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 2006; 66: 828-838.
181. -/- mice. Helicobacter. 2007; 12: 598-604.
182. Chichlowski M, Hale LP,. Effects of Helicobacter infection on research: the case for eradication of Helicobacter from rodent research colonies. Comp Med. 2009; 59: 10-17.
183. Geier MS, Butler RN, Howarth GS,. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol Ther. 2006; 5: 1265-1269.
184. Goldin BR, Gorbach SL,. Alterations of the intestinal microflora by diet, oral antibiotics, and Lactobacillus: decreased production of free amines from aromatic nitro compounds, azo dyes, and glucuronides. J Natl Cancer Inst. 1984; 73: 689-695.
185. Goldin BR, Swenson L, Dwyer J, et al. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J Natl Cancer Inst. 1980; 64: 255-261.
186. Rowland IR, Rumney CJ, Coutts JT, et al. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis. 1998; 19: 281-285.
187. Nowak A, Libudzisz Z,. Ability of probiotic Lactobacillus casei DN 114001 to bind or/and metabolise heterocyclic aromatic amines in vitro. Eur J Nutr. 2009; 48: 419-427.
188. Zsivkovits M, Fekadu K, Sontag G, et al. Prevention of heterocyclic
189. Pool-Zobel BL, Bertram B, Knoll M, et al. Antigenotoxic properties of lactic acid bacteria in vivo in the gastrointestinal tract of rats. Nutr Cancer. 1993; 20: 271-281.
190. Reddy BS, Rivenson A,. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5- f]quinoline, a food mutagen. Cancer Res. 1993; 53: 3914-3918.
191. Pool-Zobel BL, Neudecker C, Domizlaff I, et al. Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer. 1996; 26: 365-380.
192. Porschen R, Robin U, Schumacher A, et al. DNA aneuploidy in Crohn's disease and ulcerative colitis: results of a comparative flow cytometric study. Gut. 1992; 33: 663-667.
193. Sjoqvist U, Befrits R, Soderlund S, et al. Colorectal cancer in colonic Crohn's disease-high frequency of DNA-aneuploidy. Anticancer Res. 2005; 25: 4393-4397.
194. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992; 103: 1611-1620.
195. Balish E, Warner T,. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol. 2002; 160: 2253-2257.
196. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005; 128: 891-906.
197. Wang X, Huycke MM,. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology. 2007; 132: 551-561.
198. Chu FF, Esworthy RS, Chu PG, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res. 2004; 64: 962-968.
199. Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000; 47: 397-403.
200. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009; 461: 1282-1286.
201. Scheppach W,. Effects of short chain fatty acids on gut morphology and function. Gut. 1994; 35: S35-38.
202. Heerdt BG, Houston MA, Augenlicht LH,. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ. 1997; 8: 523-532.
203. Hague A, Elder DJ, Hicks DJ, et al. Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer. 1995; 60: 400-406.
204. Bordonaro M, Lazarova DL, Sartorelli AC,. Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer? Oncol Res. 2008; 317: 1-9.
205. Bolden JE, Peart MJ, Johnstone RW,. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-784.
206. Ruemmele FM, Schwartz S, Seidman EG, et al. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut. 2003; 52: 94-100.
207. Bonnotte B, Favre N, Reveneau S, et al. Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ. 1998; 5: 480-487.
208. Park JY, Helm JF, Zheng W, et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008; 36: e32-39.
209. Bennett KL, Karpenko M, Lin MT, et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res. 2008; 68: 4494-4499.
210. Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008; 112: 2013-2016.
211. Thangaraju M, Cresci GA, Liu K, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009; 69: 2826-2832.
212. Marshall BJ,. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 1995; 274: 1064-1066.
213. Min/+ mouse. Infect Immun. 2008; 76: 2758-2766.
214. Jones SE, Versalovic J,. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 2009; 9: 35.
215. Qin H, Zhang Z, Hang X, et al. L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells. BMC Microbiol. 2009; 9: 63.
216. Lievin-Le Moal V, Amsellem R, Servin AL, et al. Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut. 2002; 50: 803-811.
217. Resta-Lenert S, Barrett KE,. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut. 2003; 52: 988-997.
218. Pagnini C, Saeed R, Bamias G, et al. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci U S A. 2010; 107: 454-459.
219. Sartor RB,. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005; 21: 44-50.
220. de Sablet T, Chassard C, Bernalier-Donadille A, et al. Human microbiota-secreted factors inhibit shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7. Infect Immun. 2009; 77: 783-790.
221. Cash HL, Whitham CV, Behrendt CL, et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006; 313: 1126-1130.
222. Salzman NH, Hung K, Haribhai D, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol. 2010; 11: 76-83.
223. Hooper LV, Stappenbeck TS, Hong CV, et al. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003; 4: 269-273.
224. Abraham C, Cho J,. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 1090-1100.
225. Ivanov, II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139: 485-498.
226. Mazmanian SK, Round JL, Kasper DL,. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008; 453: 620-625.
227. Preidis GA, Versalovic J,. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009; 136: 2015-2031.
228. Wlodarska M, Finlay BB,. Host immune response to antibiotic perturbation of the microbiota. Mucosal Immunol. 2010; 3: 100-103.
229. Turnbaugh PJ, Gordon JI,. The core gut microbiome, energy balance and obesity. J Physiol. 2009; 587: 4153-4158.
230. Hoffmann C, Hill DA, Minkah N, et al. Community-wide response of the gut microbiota to enteropathogenic Citrobacter rodentium infection revealed by deep sequencing. Infect Immun. 2009; 77: 4668-4678.
231. Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007; 2: 204.
232. Bouskra D, Brezillon C, Berard M, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature. 2008; 456: 507-510.
233. Vaishnava S, Behrendt CL, Ismail AS, et al. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A. 2008; 105: 20858-20863.
234. Slack E, Hapfelmeier S, Stecher B, et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science. 2009; 325: 617-620.
235. Zhang C, Zhang M, Wang S, et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 2010; 4: 232-241.
236. aCani PD, Delzenne NM,. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009; 15: 1546-1558.
237. ACS. What are the risk factors for colorectal cancer? 2010. Available at:.
238. Bingham S, Riboli E,. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer. 2004; 4: 206-215.
239. Yang L, Lu X, Nossa CW, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009; 137: 588-597.